Nucala
Author: Chris Mulligan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils. The drug inhibits the binding of IL-5 to the receptors on the surface of eosinophils, thereby reducing blood, tissue, and sputum eosinophil levels. Nucala gained US and EU approvals for use in asthma in November 2015 and December 2015, respectively. In Japan, the drug was approved in March 2016.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Nucala : Chronic obstructive pulmonary disease (COPD)
12 Nucala : Asthma
LIST OF FIGURES
9 Figure 1: Datamonitor Healthcare’s drug assessment summary of Nucala for COPD
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Nucala for COPD
20 Figure 3: Nucala for asthma – SWOT analysis
21 Figure 4: Datamonitor Healthcare’s drug assessment summary of Nucala in asthma
22 Figure 5: Datamonitor Healthcare’s drug assessment summary of Nucala in asthma
24 Figure 6: Nucala sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Nucala drug profile
7 Table 2: Nucala Phase III data in COPD
12 Table 3: Nucala drug profile
14 Table 4: Nucala pivotal trial data in asthma
17 Table 5: Nucala late-phase trial data in asthma
19 Table 6: Nucala Phase III trials in asthma
25 Table 7: Nucala sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Stiolto Respimat 
Sign up to the